# US 2013/0251685 A1 · Injectable Cross-Linked Polymeric Preparations and Uses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0251685 A1
- Document ID: US20130251685A1
- Status: Published application
- Kind: A1
- Application number: 13/874,837
- Filed: 2013-05-01
- Published: 2013-09-26
- Earliest claimed: 2003-05-05
- Assignees: Ben-Gurion University of the Negev
- Applicants: Ben-Gurion University of the Negev
- Inventors: Smadar Cohen; Jonathan Leor
- Web page: https://patentgrep.com/patent/US20130251685A1

## CPC

- A61K 35/33: Fibroblasts
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 31/734: Alginic acid
- A61K 31/738: Cross-linked polysaccharides
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- A61K 35/34: Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes (vascular smooth muscle A61K35/44)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61L 27/20: Polysaccharides
- A61L 27/52: Hydrogels or hydrocolloids
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/06: Antiarrhythmics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 19/04: for non-specific disorders of the connective tissue
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61L 2400/06: Flowable or injectable implant compositions
- A61L 2430/20: for reconstruction of the heart, e.g. heart valves
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A therapeutic composition for treatment of a body tissue which includes an aqueous solution of a cross-linked polymer being capable of: (i) maintaining a liquid state in storage at room temperature for at least 24 hours; and (ii) assuming a gel state following deposition within the body tissue. The therapeutic composition can be effectively administered into a damaged body tissue via injection or catheterization, thereby treating the damaged body tissue.

## Claims

### Claim 1

A method of treating damaged cardiac tissue in a subject in need thereof, comprising administering a pharmaceutical preparation containing a cross-linked alginate polymer by injection into damaged cardiac tissue of the subject, thereby treating the damaged cardiac tissue, wherein the pharmaceutical preparation is cross-linked by multivalent cations and has an elastic response equal to or greater than a viscous response, the alginate is present in an amount ranging from 0.1 to 4% (w/v) with a molecular weight ranging from 1 to 300 kDa, and a multivalent cation salt to polymer salt ratio ranges between 2:1 and 1:10.

### Claim 2 (depends on 1)

The method of claim 1, further comprising multiple injections of the pharmaceutical preparation.

### Claim 3 (depends on 1)

The method of claim 1, wherein the multivalent cations are selected from the group consisting of calcium, strontium, barium, magnesium, aluminum, difunctional organic cations, trifunctional organic cations, and tetrafunctional organic cations.

### Claim 4 (depends on 1)

The method of claim 1, wherein the alginate has a molecular weight ranging between 10 and 100 kDa.

### Claim 5 (depends on 1)

The method of claim 1, wherein the alginate is present in an amount ranging from 0.5 to 2% (w/v).

### Claim 6 (depends on 3)

The method of claim 3, wherein calcium ions are provided by a calcium gluconate solution.

### Claim 7 (depends on 1)

The method of claim 1, wherein the pharmaceutical preparation is injected into a myocardial scar.

### Claim 8 (depends on 1)

The method of claim 1, wherein the damaged cardiac tissue is infarcted myocardium.

### Claim 9 (depends on 1)

The method of claim 1, wherein the damaged cardiac tissue is the left ventricular wall of the subject's heart.

### Claim 10 (depends on 9)

The method of claim 9, wherein the pharmaceutical preparation thickens the left ventricular wall of the subject's heart.

### Claim 11 (depends on 1)

The method of claim 1, wherein administration of the pharmaceutical preparation ablates arrhythmias.

### Claim 12 (depends on 1)

The method of claim 1, wherein the pharmaceutical preparation is directly injected into damaged cardiac tissue of the subject.

### Claim 13 (depends on 1)

The method of claim 1, wherein the pharmaceutical preparation further comprises a therapeutic agent.

### Claim 14 (depends on 13)

The method of claim 13, wherein the therapeutic agent is selected from the group consisting of fibroblast growth factor, vascular endothelial growth factor, insulin-like growth factor, members of the TGF family, bone morphogenic proteins, platelet derived growth factors, angiopoietins, myogenic factors, transcription factors, cytokines, homeobox gene products, polynucleotides, polypeptides, hormones, anti-inflammatory drugs, anti-apoptotic drugs and antibiotic drugs.

### Claim 15 (depends on 1)

The method of claim 1, wherein the multivalent cation salt to polymer salt ratio ranges between 1:2 and 1:5.

### Claim 16 (depends on 15)

The method of claim 15, wherein the multivalent cation salt to polymer salt ratio ranges between 1:3 and 1:4.

### Claim 17 (depends on 1)

The method of claim 1, wherein the alginate is present in an amount ranging from 0.8 to 1.5% (w/v).

### Claim 18 (depends on 1)

The method of claim 1, wherein the alginate has a molecular weight ranging from 10 to 100 kDa.
